Grants and Contracts Details
Description
The goal of this project is to translate basic biologic knowledge into a practical application for enhancing the efficacy of
radiation therapy for the treatment of lung cancer. Lung cancer represents one of the great challenges of oncology. Radiation,
surgery and chemotherapy alone or in combination have been employed in attempts to improve treatment outcome. Yet over the
past 30 years the five-year survival ofIung cancer patients has only improved modestly. Advances in the understanding of
molecular pathways of cancer have progresses to the point that new biological targets for therapy and potential therapeutic agents
have been identified. Proteosome inhibitors and COX-2 inhibitors are prominent candidates for new therapeutic agents that may
enhance radiation response of tumors. Both proteosome inhibitors and COX-2 inhibitors are associated with tumor apoptosis and
limit tumor angiogenesis. Cell cultures studies demonstrate both these agents preferentially increase tumor cell sensitivity to
radiation compared to non-tumor cells. Thus, combining proteosome inhibitors and/or COX-2 inhibitors with radiation is
expected to enhance the tumor control without enhancing normal tissue toxicity. GRID radiation is a method of delivering
spatially fractionated radiation using multiple pencil beams with unirradiated segments between. The advantage of delivering
spatially fractionated radiation is the ability to kill large numbers of tumor cells while leaving islands of normal unirradiated tissue
for recovery. The killing of unirradiated tumor is thought to be mediated by the by-stander effect. In-vitro studies have found
increased cytokine production and apoptosis in cells neighboring the irradiated field after GRID treatment. Combining biologic
agents that preferentially sensitize tumor to the process of apoptosis may enhance the efficacy of radiation treatment, particularly
with GRID therapy through its known association with apoptosis and the by-stander-effect.
Status | Finished |
---|---|
Effective start/end date | 10/1/01 → 9/30/04 |
Funding
- KY Lung Cancer Research Fund: $196,922.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.